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Abstract 
Background: Plasmodium vivax infection is known to be rare in West/Central Africa, the most accepted explanation 
being the lack of expression of erythroid Duffy antigen in the local human populations. Duffy negativity prevents 
the parasite to exploit the entry mechanism on the red blood cell surface. However, there are a growing number of 
reported vivax infections in Duffy-negative individuals. Data on P. vivax circulation in Cameroon are limited. The aim of 
the study was to evaluate the P. vivax presence, and its association with the Duffy genotype in West Cameroon.
Results: Overall, 484 blood samples were collected consecutively from febrile outpatients attending the Dschang’s 
Hospital (West Cameroon) during a 3-months period. Plasmodium vivax infection was detected by PCR in 5.6% 
(n = 27/484) of the cases, representing 38.6% (n = 27/70) of all Plasmodium infections detected. All P. vivax infected 
individuals showed a Duffy-negative genotype, and the frequency of Duffy-positive individuals in the whole tested 
population was 1.7%.
Conclusions: The results of this study confirm the circulation of P. vivax in Cameroon, as well as that the lack of 
expression of Duffy-antigen does not confer full protection against vivax malaria acquisition.
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Background
The World Health Organization (WHO) has estimated 
that a total of 214 million new cases of malaria occurred 
globally in 2014, with 438,000 related deaths, mostly 
related to Plasmodium falciparum and located in sub-
Saharan Africa [1]. Plasmodium vivax is responsible 
of 8% of estimated malaria cases worldwide (about 50% 
when excluding sub-Saharan Africa), with three coun-
tries (Ethiopia, India and Pakistan) accounting for 80% of 
the cases [1]. Plasmodium vivax has a wider geographic 
distribution than P. falciparum, which is mostly preva-
lent in sub-Saharan Africa [1]. Possible explanations for 
this could be that P. vivax is able to develop at lower tem-
peratures in the vector [2, 3], and may survive for long 
periods as hypnozoite (dormant liver stage) representing 
a possible reservoir of the infection and a major obstacle 
toward vivax malaria eradication [4–6].
For a long time, scientists and decision makers have 
neglected malaria due to P. vivax because it was con-
sidered as “benign” malaria when compared with the 
“malignant” form caused by P. falciparum [2]. Clini-
cal manifestations of P. vivax infection are generally 
less severe than those related to P. falciparum infection, 
possibly because P. vivax infects mainly young red cells 
(reticulocytes), which are numerically limited (being 
<2.5% of circulating red blood cells) and appear to be less 
prone to cytoadherence or sequestration in microcircula-
tion [2, 7, 8]. Nevertheless there are still remarkably large 
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knowledge gaps on the pathophysiology of vivax malaria 
[7–9].
The human Duffy antigen receptor is the only well-
known pathway used by P. vivax for erythrocyte invasion, 
through the interaction with the P. vivax Duffy bind-
ing protein (PvDBP) [10]. The Duffy antigen, also called 
Duffy Antigen Receptor for Chemokines (DARC), is a 
multimeric membrane protein organized into 7 trans-
membrane domains that is present in erythrocytes, 
endothelial cells (bone marrow, lung, kidney, adrenal 
gland, thyroid, spleen, colon), and epithelial cells (kid-
ney collecting ducts, type-I alveolar lung cells, Purkinje 
cells of the cerebellum) [11]. The expression of the Duffy 
antigen on erythrocytes is linked to a single nucleotide 
polymorphism (SNP) (-33T>C) in the erythroid-spe-
cific promoter region (GATA box) of the DARC gene 
on chromosome 1 [12]. In carriers of the homozygous 
variant (-33CC) the Duffy antigen on the erythrocytes 
is absent (Duffy-negative phenotype), while in heterozy-
gous carriers (-33TC) its expression is reduced [12, 13]. 
The Duffy-negative phenotype reaches frequency of 
95–100% in West and Central African populations (and 
their descendants) and is extremely rare outside Africa 
[14], possibly explaining the low circulation of P. vivax in 
these geographical areas [1]. However, there is a growing 
number of reported cases of P. vivax infection in individ-
uals with Duffy-negative erythroid phenotype, leading to 
hypothesize the existence of an alternative pathway for P. 
vivax erythrocyte invasion [12, 13, 15].
In Cameroon, a country of the Central Africa sub-
region, P. falciparum is broadly considered responsible 
of up to 100% of malaria cases [1], and the vast majority 
(95–99%) of the population has a Duffy-negative eryth-
roid phenotype [14]. Very recently P. vivax infections 
have been reported in Cameroon among symptomatic 
[16, 17] and asymptomatic [18] Duffy-negative individu-
als from different regions (South, South-West, Littoral, 
East) in the southern part of the country. The primary 
objective of the present study was to evaluate the P. vivax 
circulation among febrile outpatients seeking medical 
care in Dschang, West region of Cameroon. A second 
objective was to explore the Duffy antigen genotype fre-
quency among the study population.
Methods
Study area and sample collection
The study was carried out in Dschang, chief town of the 
Menoua Division, West region of Cameroon. The city of 
Dschang (5°27′N; 10°04′E), which is located at an alti-
tude of 1400 masl, has an average annual temperature 
of 20.5 ± 6  °C, with February being the hottest month. 
Four seasons can be distinguished as follows: the main 
dry season (November to mid-March), the short rainy 
season (mid-March to May), the short dry season (June 
to July) and the main rainy season (August to October) 
[19]. According to local health authorities, the 2012 esti-
mated district’s population was of 218,006 inhabitants 
(17% under-5  years old children), with the vast major-
ity belonging to Bamiléké, a Bantu-related ethnic group. 
The local economy is mainly based on agriculture, live-
stock and trade. The presence of non-African people in 
Dschang is very limited, and foreign tourism is almost 
absent.
Samples were collected consecutively from febrile out-
patients (all native Cameroonian) attending the District 
Hospital of Dschang, West Cameroon, during a 3-months 
period (December to February). Demographic and essen-
tial clinical data were collected from each patient. After 
venepuncture, an aliquot of 100 µl of whole venous blood 
was spotted on filter paper (Whatman, UK), air-dried 
at room temperature, and then stored in locked bags at 
+4 °C.
Nucleic acid extraction, analysis and sequencing reactions
Human/parasite DNA was extracted by automated 
method using Maxwell®16 instrument (Promega, Madi-
son, WI, USA) from the dried blood spots (DBS) col-
lected. The presence of nucleic acids or PCR inhibitors 
in the extracted DBS was determined by amplification 
of a human house-keeping gene (acid phosphatase 1) 
[20]. The PCR analysis of the four mains species of Plas-
modium (P. falciparum, P. vivax, Plasmodium ovale, 
Plasmodium malariae) was performed by a nested-
PCR of specific 18S rRNA gene fragments as previously 
described [21]. Four positive control DNA for all Plasmo-
dium species and two negative (for the outer and nested 
PCR, respectively) were used in the genetic analysis [22].
To assess the specificity of the PCR analysis, four 
amplicons of P. vivax positive samples underwent 
sequencing reactions (Fig.  1) and they underwent to a 
further amplification of a region of the 18S rRNA gene 
different from the target region we used for the molecu-
lar detection [21]. Sequencing analyses were performed 
using an automated DNA sequencer (CEQ 8000, Beck-
man®). Sequencing alignments were carried out using 
ClustalX [23].
Genotyping of erythrocytes Duffy antigen by melting 
curve analysis
To explore the possible susceptibility of the study popu-
lation to P. vivax infection, the Duffy antigen genotype 
due to the SNP -33T>C was investigated. Duffy geno-
type was analysed through the melting curve profile of a 
new-designed PCR method. The PCR amplified a frag-
ment of 178  bp (from position 186–363, an. JN251917), 
encompassing the SNP in the GATA box (position 234). 
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The sensor-probe was designed on the negative-phe-
notype. The PCR reaction was set-up in a final volume 
of 20 µl using the XtraTaq pol system [24] with 0.3 µM 
of forward (5′-CCTGTCCCTGCCCAGAA-3′) and 
0.5 µM of reverse (5′-GGCATAGGGATAAGGGACT-3′) 
primers, 0.2  µM each of the anchor-probe (5′CY5-
ACAGCCGTCCCAGCCC-3′PHO) and sensor probe 
(5′-TTACCTTGGAAGCACAGGCGC-3′FLU), 0.01% of 
BSA and 3 µl of DNA. The reactions were performed on 
a Light Cycler or LC480 instruments (Roche Diagnos-
tics, Switzerland). The amplification program consisted of 
95  °C for 30 s and then 45 cycles of 95  °C for 10 s, 52  °C 
for 30 s and 72 °C for 10 s. The transition rates (TR) were 
20 °C/s. The melting curve analysis consisted of 95 °C for 
30 s, 55 °C for 2 min with a TR of 20 °C/s, and an acqui-
sition step from 50 to 75  °C with a TR of 0.1  °C/s. The 
fluorescence signal was acquired using channel 670/530. 
A melting curve analysis was performed on two homozy-
gous controls showing two different peak profiles at 60.5 
and 64.5 °C melting temperature, corresponding to -33TT 
(Caucasian, Duffy positive) and -33CC (Cameroonian, 
Duffy negative) genotypes, respectively (Fig. 2c). The posi-
tive controls were also sequenced (Fig. 2a, b).
Statistical analysis
Categorical variables (sex, provenance, ethnicity, preg-
nancy, comorbidities, previous anti-malarial self-medica-
tion) were reported as absolute number and percentage, 
and continuous data (age, days of diagnostic delay) were 
expressed as median and interquartile range. Chi square 
test (for categorical variables) and Mann–Whitney test 
(for continuous variables) were used to compare Plas-
modium spp. positive vs negative and P. falciparum posi-
tive vs P. vivax positive results. D’Agostino and Pearson 
omnibus normality test was applied to confirm the non-
normal distribution of quantitative parameters. Odds 
ratio (OR) with 95% confidence interval (CI) were also 
calculated. The R (version 2.15.0, R foundation statisti-
cal Computing) and Prism (version 5.00.288, GraphPad 
Software, Inc) were employed as statistical software. 
Evaluation of Hardy–Weinberg equilibrium (HWE) was 
performed using the HWSIM software [25] and Monte-
Carlo permutation test performed when genotypic 
classes had an expected cell size of less than five.
Results
A total of 484 samples were consecutively collected from 
febrile outpatients. Population’s characteristics are sum-
marized in Table 1. Malaria parasite DNA was identified 
by nested-PCR in 70 samples (14.5%): 68 cases of Plas-
modium mono-infections (42 P. falciparum, 25 P. vivax, 
and 1 P. malariae) and 2 cases of P. falciparum/P. vivax 
co-infections. Because of the unexpected frequency of P. 
vivax, in order to assess the specificity of the molecular 
analysis, four amplicons were purified, sequenced and 
aligned confirming the specificity of the analysis (Fig. 1a). 
Additionally, a subset of P. vivax positive samples by 
molecular analysis was analyzed by amplifying a different 
region of the rRNA 18S gene [26]: three amplicons were 
sequenced and aligned confirming the P. vivax diagnosis 
(Fig.  1b). The proportion of P. falciparum and P. vivax 
infections was 9.1% (n = 44/484) and 5.6% (n = 27/484), 
respectively. Notably, 38.6% (n = 27/70) of Plasmodium 
positive PCR results were due to P. vivax infection. Male 
gender was associated with Plasmodium PCR positive 
result (OR 2.3; 95% CI 1.39–3.89; P =  0.0014) at uni-
variate analysis (Table 1). No other correlation was found 
between PCR results (or Plasmodium species detected) 
and other demographic or clinical data collected 
(Table 1).
The Duffy antigen genotype (Fig.  2; Table  2) was 
assessed in a subset of 228 unrelated samples (27 P. vivax 
Fig. 1 Plasmodium vivax (a) and Plasmodium spp. (b) sequence alignment* DNA sequence alignment of the four reference species (P. vivax, 
an. U03079; P. malariae, an. M54897; P. ovale an. L48987; P. falciparum, an. JQ627152) with four P. vivax positive amplicons (n. 424, 455, 452, 457) 
sequenced (A) and three Plasmodium spp. positive samples (n. 455, 365, 483) sequenced according to Rougemont et al. [26] (B). *Identical nucleo-
tides are shown as dots, mismatches and gaps are highlighted in gray
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positive and 201 randomly selected). Two Duffy-positive 
(-33TT), two heterozygous (-33TC), and 224 Duffy-
negative (-33CC) genotypes were detected. All P. vivax 
infected individuals showed a Duffy-negative genotype. 
Overall, the frequency of the -33T allele was 1.3%, cor-
responding to a frequency of 1.7% (n = 4/228) of Duffy-
positive phenotypes (homo- and heterozygotes). Then the 
HWE was tested. A lack of heterozygotes was assessed 
using Chi square analysis (χ2 =  99.99, 1 df, P <  0.001). 
The Monte-Carlo permutation test (10,000 iterations) 
gave a P = 0.0629.
Discussion
The evidence of P. vivax infection in Duffy negative 
febrile individuals from the West Region of Cameroon is 
reported. The study population was mainly represented 
Fig. 2 Duffy antigen genotyping (SNP -33T>C in GATA box, DARC gene) by melting curve analysis. a Chromatogram of the Caucasian Duffy-posi-
tive phenotype (-33TT genotype), reference sample. b Chromatogram of the Cameroonian Duffy-negative phenotype (-33CC genotype), reference 
sample. c Melting curve analysis of the two reference samples: melting temperatures of 60.5 and 64.5 °C for Duffy-positive (Caucasian) and Duffy-
negative (Cameroonian), respectively. d Melting curve analysis of a representative group of samples, including the two reference samples. Two 
heterozygous samples (thick red and blue lines) are also shown. Negative controls are in the lower part of the melting curves of c, d
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by young individuals (median age 24 years), and in par-
ticular children. Notably, the only factor associated with 
a higher frequency of malaria infection was male gender 
(see Table  1): a possible explanation of this statistically 
significant difference could be that male patients seek 
for medical advice only in more severe cases, or due to 
chance alone.
Historically, P. vivax infection has been considered as 
“benign” malaria, and the Duffy-negative phenotype as 
full protective against P. vivax infection. But, recently, 
both axioms have been questioned. In fact, there are sev-
eral reports of severe vivax malaria [4, 8, 9] as well as of 
P. vivax infection among Duffy-negative individuals from 
Angola [27], Cameroon [16–18], Equatorial Guinea [27], 
Table 1 Study population characteristics and comparison between Plasmodium spp. (P. spp.) PCR-pos vs PCR-neg groups, 
and between PCR-pos P. falciparum (Pf) vs P. vivax (Pv) patients (univariate analysis)
[IQR] interquartile range, AHT arterial hypertension
a 68 Plasmodium mono-infections (42 P. falciparum, 25 P. vivax, 1 P. malariae) and 2 P. falciparum + P. vivax co-infections
b Two co-infected (P. falciparum + P. vivax) patients not included in the analysis
c Only among women
d Anti-malarial drugs taken after the onset of fever and before the medical consultation 
Variable Total population P. spp. PCR− 
(n = 414)
P. spp. PCR+ 
(n = 70)a
P value Pf PCR+ (n = 42)b Pv PCR+ (n = 25)b P value
Age (years), n (%)
 ≤5 131 (27.1%) 112 (27.1%) 19 (27.1%) 0.153 11 (26.2%) 7 (28.0%) 0.906
 6–14 31 (6.4%) 26 (6.3%) 5 (7.1%) 2 (4.8%) 2 (8%)
 15–24 91 (18.8%) 78 (18.8%) 13 (18.6%) 9 (21.4%) 4 (16%)
 25–64 198 (40.9) 171 (41.3%) 27 (38.6%) 17 (40.5%) 9 (36%)
 ≥65 33 (6.8%) 27 (6.5%) 6 (8.6%) 3 (7.1%) 3 (12%)
 Median [IQR] 24 [4–40] 23 [4–43] 24 [4–39] 0.732 23 [4–42] 21 [3–37] 0.721
Sex, n (%)
 Male 191 (39.5%) 151 (36.5%) 40 (57.1%) 0.001 24 (57.1%) 14 (56%) 1.000
 Female 293 (60.5%) 263 (63.5%) 30 (42.9%) 18 (42.9%) 11 (44%)
Provenance, n (%)
 Urban 316 (65.3%) 264 (63.8%) 52 (74.3%) 0.103 30 (71.4%) 19 (76%) 0.780
 Rural 168 (34.7%) 150 (36.2%) 18 (25.7%) 12 (28.6%) 6 (24%)
Ethnicity, n (%)
 Bamiléké 429 (89%) 363 (88%) 66 (94%) 0.151 40 (95%) 24 (96%) 1.000
 Others 55 (11%) 51 (12%) 4 (6%) 2 (5%) 1 (4%)
Co-morbidity, n (%)
 No 448 (92.6%) 383 (92.5%) 65 (92.9%) 1.000 38 (90.5%) 24 (96%) 0.643
 Yes 36 (7.4%) 31 (7.5%) 5 (7.1%) 4 (9.5%) 1 (4)
 Diabetes 8 (1.6%) 8 (1.9%) 0 (0%) 0 (0%) 0 (0%)
 AHT 19 (3.9%) 15 (3.7%) 4 (5.7%) 3 (7.1%) 1 (4%)
 AHT + diabetes 5 (1.1%) 5 (1.2%) 0 (0%) 0 (0%) 0 (0%)
 AHT + bronchial 
asthma
1 (0.2%) 1 (0.2%) 0 (0%) 0 (0%) 0 (0%)
 Bronchial asthma 1 (0.2%) 1 (0.2%) 0 (0%) 0 (0%) 0 (0%)
 HIV infection 1 (0.2%) 1 (0.2%) 0 (0%) 0 (0%) 0 (0%)
 HCV infection 1 (0.2%) 0 (0%) 1 (1.4%) 1 (2.4%) 0 (0%)
Pregnancy, n (%)c
 Yes 17 (5.8%) 15 (5.7%) 2 (6.7%) 0.688 0 (0%) 2 (18.2%) 0.135
 No 276 (94.2%) 248 (94.3%) 28 (93.3%) 18 (100%) 9 (81.8%)
Previous anti-malarial self-medication, n (%)d
 Yes 198 (40.9%) 168 (40.6%) 30 (42.9%) 0.952 18 (42.9%) 11 (44%) 0.952
 No 286 (59.1%) 246 (59.4%) 40 (57.1%) 24 (57.1%) 14 (56%)
Diagnostic delay (days)
 Median [range] 3 [2–7] 3 [1–6] 3 [2–7] 0.144 3.5 [2–7] 3 [2–7] 0.707
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Ethiopia [28, 29], Kenya [30], Madagascar [13], Maurita-
nia [31] and Brazil [32, 33]. Three recent studies showed 
the circulation of P. vivax in the southern part of Cam-
eroon (Table 3; Fig. 3) [16–18]. In comparison with these 
studies [16–18] data from the West region of Cameroon 
confirm the circulation of P. vivax in native individu-
als with Duffy-negative genotype (Fig. 3), and showed a 
higher relative proportion of P. vivax infection, possibly 
linked to the higher altitude of the study area. Moreo-
ver, considering that the study was conducted when the 
anopheline density was at its lowest (main dry season) 
[19], these data possibly underestimate the real circula-
tion of P. vivax in West-Cameroon, where climatic con-
ditions during the two rainy seasons may facilitate its 
circulation [2, 3].
The Cameroonian population, as well as other West 
and Central African populations (and their descendants), 
show a 95–99% frequency of Duffy-negative phenotype 
[14], possibly as a consequence of the positive selective 
process linked to an ancient (100,000 years) presence of 
P. vivax in sub-Saharan Africa [3]. In this study, the HWE 
assessment on the Duffy genotype distribution showed 
a lack of heterozygotes (using Chi square analysis), and 
the Monte-Carlo permutation test being on the verge 
of significance. It is noteworthy that the slight depar-
ture from the HWE of genotype frequencies for Duffy 
is probably due to the effect of natural selection exerted 
by P. vivax (one of the theoretical assumptions for HWE 
is absence of natural selection), similar to that seen in 
Madagascar [34]. It is also worth considering the possible 
deviation from HWE with respect to the biased sampling 
of febrile individuals.
According to some authors, the maintenance of P. vivax 
circulation in Duffy-negative population context is pos-
sibly related to the presence of reservoirs of Duffy-pos-
itive individuals (1–5%) presumably present in the local 
population [5] or, in restricted areas, to P. vivax and/or 
P. vivax-like infections found in apes [35]. Moreover, P. 
vivax circulation might be facilitated by the highly spe-
cific vectorial competence showed by the Anopheles gam-
biae and Anopheles funestus complexes that circulate in 
Africa [30, 36]. In this study, the measure Duffy antigen 
expression on erythrocytes at the protein level was not 
assessed; however, the Duffy genotype predicts its pheno-
type with high consistency [13]. In the population study, 
the -33T allele frequency was 1.3%, confirming a mini-
mal presence of Duffy-positive individuals also within 
the Bamiléké ethnic group in West Cameroon. Moreo-
ver, the country (mainly in the southern part) accounts 
for a significant population of great apes; a recent study 
has showed a relevant 2.3% (n =  45/2168) of P. vivax-
like infection among great apes living in Cameroon [37]. 
These elements, together with the climate and geographic 
variety of Cameroon, suggest that P. vivax circulates in 
different areas of the country. Some investigators suggest 
that P. vivax may be in the process to evolving the abil-
ity to infect Duffy-negative erythrocytes [13, 15], possibly 
involving parasite DBPs and/or reticulocyte binding pro-
teins [38, 39]. The alternative yet-uncharacterized Duffy-
independent erythrocyte invasion pathway is likely to be 
less efficient [13], leading to lower level of parasitaemia 
as observed in carriers of heterozygous Duffy-genotype 
Table 2 Duffy-antigen genotyping results (n = 228)
PCR-analysis results Duffy-antigen genotyp-
ing
-33TT -33TC -33CC
P. falciparum positive 0 0 11
P. malariae positive 0 0 1
P. vivax positive 0 0 25
P. falciparum/P. vivax positive (co-infection) 0 0 2
Plasmodium negative 2 2 185
Total 2 2 224
Table 3 Vivax malaria in Cameroon
a Relative proportion of P. vivax infection among total malaria cases
b Five sites in southern Cameroon (Littoral, South, Centre and East regions)
c All symptomatic (febrile) individuals
d South-West region of Cameroon
e All asymptomatic individuals
f West region of Cameroon
Study (ref.) Study site Total population, n Malaria cases, n (%) Vivax malaria cases
n %a Duffy neg, n
[16] Five sitesb 485c 201 (41.4) 8 4 8/8
[17] Douala city 60c 43 (71.7) 10 23.2 10/10
[18] Bolifamba villaged 269e 87 (32.3) 13 4.8 6/13
Present study Dschangf 484c 70 (14.5) 27 38.6 27/27
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(-33TC) from Papa New Guinea [40]. Thus, the reason 
underlying the reported P. vivax infection in Duffy-neg-
ative individuals from context with very low presence 
of Duffy-positive phenotypes, as in the present study, 
remains unclear. All these elements underline the basic 
knowledge gaps of P. vivax life cycle [7–9] and the need 
to assess the real circulation of P. vivax in sub-Saharan 
Africa [41] also in the broader perspective of malaria 
eradication worldwide.
Although P. vivax is susceptible to several anti-malar-
ial drugs (i.e. chloroquine, quinine, artemisinin and its 
derivatives), primaquine (PQ) is the only licensed drug 
active against the hypnozoites to prevent P. vivax relapses 
from the liver [6]. Moreover, a true resistance to PQ in 
P. vivax hypnozoites has not been described, suggesting 
a role for host factors in drug failure [42]. Primaquine 
is metabolized in the liver by the enzyme cytochrome 
P450-2D6 (CYP2D6), possibly leading to a metabo-
lite responsible for hypnozoite killing [42]. Thus, defec-
tive CYP2D6 metabolism could be associated with PQ 
failure [43]. Furthermore, the risk of acute haemolytic 
anaemia in carriers of glucose-6-phosphate dehydroge-
nase (G6PD) deficiency is a safety concern for PQ use 
(14 days at 0.5 mg/kg), and data on African G6PD defi-
ciency are not exhaustive [44]. Available data related to 
G6PD in Cameroon are scarce, with one published sur-
vey reporting the G6PD deficiency prevalence being 6.6% 
[45]. Thus, considering the observed P. vivax circulation 
in different regions of Cameroon, larger studies assessing 
G6PD deficiency prevalence and CYP2D6 polymorphism 
frequency in the whole country are necessary in order to 
ensure a safer therapeutic use of PQ.
The present study has some limitations. Data on para-
sitaemia of Plasmodium species infections are lacking 
because the diagnosis was based only on a molecular 
qualitative technique and because of the lack of experi-
enced local microscopists. Moreover, although 40% of 
the participants reported anti-malarial self-medication 
before the medical consultation, data on drugs, dosage 
and duration were not reported, as well as follow-up data 
of infected cases.
Conclusion
The present study reports the molecular evidence of P. 
vivax circulation in the West region of Cameroon among 
symptomatic Duffy-negative outpatients, perhaps with 
the highest proportion of P. vivax infection when com-
pared to previous studies in the country [16–18]. These 
results suggest the need for assessing the real circula-
tion of P. vivax in West/Central African countries to 
plan public health activities in order to improve the local 
microscopic diagnostic capacity, and to ensure a more 
effective and safer therapeutic management of vivax 
malaria attacks and relapses.
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W West, L Littoral, C Centre, S South, E East. Study sites: 1 Bolifamba 
village (South-West Region): 13/269 (4.8%) P. vivax infections [18]; 2 
Douala (Littoral Region): 2/52 (3.8%) [16] and 6/60 (10%) [17] P. vivax 
infections; 3 Ebolowa (South Region): 3/60 (5%) P. vivax infections [16]; 
4 Yaoundé (Centre Region): 1/29 (3.4%) P. vivax infection [16]; 5 Bert-
oua (East region): 2/25 (8%) P. vivax infections [16]; 6 Dschang (West 
Region): 27/484 (5.6%) P. vivax infections (present study)
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